Detalhe da pesquisa
1.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684370
2.
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Int J Cancer
; 146(2): 413-423, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246277
3.
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.
Clin Chem
; 65(10): 1267-1275, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31387885
4.
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Br J Clin Pharmacol
; 85(6): 1357-1366, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30811063
5.
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(12): 1732-1742, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751846
6.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892145
7.
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 16(5): 531-40, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25864104
8.
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Lancet Oncol
; 16(4): 457-64, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795402
9.
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.
BMC Cancer
; 14: 156, 2014 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24597959
10.
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
BMC Cancer
; 14: 870, 2014 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25420707
11.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Lancet Healthy Longev
; 5(3): e182-e193, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38432247
12.
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Lancet Healthy Longev
; 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759667
13.
[French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment]. / Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures Principes généraux de traitement.
Bull Cancer
; 111(4): 393-415, 2024 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-38418334
14.
[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib]. / Association inhabituelle d'inhibiteurs de BRAF et de MEK : réponse clinique d'un mélanome métastatique traité par dabrafénibcobimétinib.
Bull Cancer
; 110(7-8): 865-868, 2023.
Artigo
em Francês
| MEDLINE | ID: mdl-36966054
15.
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Oncologist
; 17(9): 1213-20, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22907974
16.
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Oncologist
; 17(2): 260-6, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285963
17.
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.
Cancer Res
; 82(6): 974-985, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078815
18.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med
; 359(11): 1116-27, 2008 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18784101
19.
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
BMC Cancer
; 11: 72, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21324142
20.
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Lancet Oncol
; 11(10): 942-9, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20864406